The company recently invested an additional €90m to expand its capabilities at its contact lens manufacturing plant in ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic competition in ...

Learn more about whether Bausch + Lomb Corporation or Omnicell, Inc. is a better investment based on AAII's A+ Investor ...

Meet the new Valeant: Drugmaker drops tainted name to become Bausch Health in July rebrand A buyout would be one of the largest private equity healthcare deals of the year as Bausch + Lomb has an ...

Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69 ... and contact lens care products ...

HighTower Advisors LLC raised its stake in shares of Bausch + Lomb Co. (NYSE:BLCO – Free Report) by 14.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 24,661 shares of the ...